XOMA Corporation
Index- P/E31.87 EPS (ttm)0.54 Insider Own0.20% Shs Outstand11.33M Perf Week-9.99%
Market Cap208.24M Forward P/E- EPS next Y-0.02 Insider Trans-73.74% Shs Float10.81M Perf Month-33.01%
Income12.20M PEG1.68 EPS next Q-0.10 Inst Own60.10% Short Float3.47% Perf Quarter-12.77%
Sales40.90M P/S5.09 EPS this Y-16.60% Inst Trans-0.56% Short Ratio11.61 Perf Half Y-33.29%
Book/sh12.35 P/B1.39 EPS next Y-122.50% ROA8.30% Target Price62.50 Perf Year-42.48%
Cash/sh7.30 P/C2.36 EPS next 5Y19.00% ROE9.60% 52W Range16.96 - 39.02 Perf YTD-17.46%
Dividend- P/FCF9.21 EPS past 5Y15.70% ROI12.10% 52W High-55.38% Beta1.09
Dividend %- Quick Ratio11.40 Sales past 5Y47.00% Gross Margin- 52W Low2.65% ATR1.77
Employees12 Current Ratio11.40 Sales Q/Q675.00% Oper. Margin52.60% RSI (14)34.03 Volatility9.78% 8.41%
OptionableYes Debt/Eq0.00 EPS Q/Q54.20% Profit Margin29.90% Rel Volume0.94 Prev Close17.21
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume32.35K Price17.41
Recom2.30 SMA20-14.39% SMA50-27.74% SMA200-27.60% Volume12,511 Change1.16%
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-22-15Downgrade Ladenburg Thalmann Buy → Neutral
Oct-10-14Resumed ROTH Capital Buy $9
Apr-29-14Upgrade MLV & Co Hold → Buy $7
Mar-11-14Downgrade MLV & Co Buy → Hold $8 → $7
Mar-05-14Reiterated Ladenburg Thalmann Buy $6.50 → $10
Oct-31-13Reiterated MLV & Co Buy $7.50 → $8
May-09-13Reiterated Ladenburg Thalmann Buy $5 → $6
May-14-12Initiated Cowen & Co Outperform
Mar-31-11Reiterated MLV Capital Buy $12 → $10
May-07-22 08:27AM  
May-05-22 08:55AM  
May-03-22 08:15AM  
Apr-20-22 08:24AM  
Mar-21-22 07:30AM  
Mar-15-22 06:21AM  
Mar-10-22 09:43AM  
Mar-08-22 07:30AM  
Mar-01-22 07:30AM  
Feb-17-22 07:30AM  
Jan-21-22 10:21AM  
Dec-23-21 07:30AM  
Dec-21-21 07:30AM  
Dec-16-21 07:30AM  
Nov-22-21 11:46AM  
Nov-15-21 06:01AM  
Nov-04-21 10:15AM  
Oct-28-21 03:06PM  
Oct-27-21 04:50AM  
Oct-14-21 06:57AM  
Oct-08-21 03:35AM  
Sep-22-21 07:30AM  
Sep-21-21 12:33PM  
Sep-20-21 07:30AM  
Sep-13-21 07:30AM  
Sep-07-21 01:49PM  
Aug-10-21 04:35PM  
Aug-05-21 08:45AM  
Jul-29-21 03:05PM  
Jul-28-21 07:30AM  
Jul-15-21 06:38AM  
Jun-23-21 03:16PM  
Jun-21-21 07:30AM  
Jun-08-21 10:38AM  
May-21-21 08:00AM  
May-06-21 09:15AM  
May-03-21 07:30AM  
Apr-15-21 09:05AM  
Apr-12-21 07:30AM  
Apr-06-21 07:02PM  
Apr-05-21 04:05PM  
Mar-23-21 08:00AM  
Mar-22-21 07:30AM  
Mar-10-21 08:45AM  
Mar-03-21 05:16AM  
Mar-02-21 12:30PM  
Feb-23-21 04:05PM  
Jan-04-21 04:05PM  
Dec-30-20 05:50AM  
Dec-21-20 05:00PM  
Dec-10-20 11:45PM  
Dec-08-20 08:38AM  
Nov-16-20 07:30AM  
Nov-12-20 09:47AM  
Nov-11-20 07:30AM  
Nov-06-20 08:56AM  
Nov-05-20 09:35AM  
Nov-03-20 07:30AM  
Oct-28-20 07:30AM  
Oct-14-20 07:30AM  
Sep-23-20 12:15PM  
Sep-10-20 11:18AM  
Sep-02-20 07:30AM  
Aug-17-20 07:19AM  
Aug-06-20 07:50PM  
Aug-05-20 07:30AM  
Jul-28-20 12:33PM  
Jul-01-20 07:30AM  
Jun-29-20 07:30AM  
Jun-24-20 11:00PM  
Jun-22-20 01:58PM  
May-11-20 01:42PM  
May-05-20 09:45AM  
Apr-28-20 12:39PM  
Apr-27-20 12:31PM  
Mar-13-20 10:53AM  
Mar-10-20 07:30AM  
Mar-09-20 05:00AM  
Feb-27-20 12:30PM  
Feb-25-20 04:30PM  
Jan-22-20 01:02PM  
Dec-26-19 07:12AM  
Dec-23-19 04:00PM  
Dec-20-19 04:35PM  
Dec-16-19 09:34AM  
Dec-05-19 05:04PM  
XOMA Corporation, a biotechnology royalty aggregator, engages in helping biotech companies for improving human health. The company acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. It acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance internal drug candidate or for general corporate purposes. The company has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BURNS THOMAS M.SVP, Finance & CFOMar 23Option Exercise4.031616496,716Mar 23 06:52 PM
Neal James RCEOMar 23Option Exercise4.031,1114,47712,933Mar 23 06:52 PM
Neal James RCEOMar 23Sale30.021,11133,34811,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 23Sale30.001614,8306,555Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 22Option Exercise4.032,3399,4268,894Mar 23 06:52 PM
Neal James RCEOMar 22Option Exercise4.032,3399,42614,161Mar 23 06:52 PM
Neal James RCEOMar 22Sale30.022,33970,20911,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 22Sale30.022,33970,2096,555Mar 23 06:52 PM
Neal James RCEOMar 21Option Exercise4.0350,000201,50061,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 21Option Exercise4.0312,00048,36018,555Mar 23 06:52 PM
Neal James RCEOMar 21Sale29.0050,0001,450,25011,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 21Sale29.0012,000348,0606,555Mar 23 06:52 PM
Neal James RCEOJun 25Sale33.629,027303,47411,822Jun 29 05:09 PM